



Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Company release

Nanoform Finland Plc

October 27, 2022

19:15 Finnish time / 18:15 Swedish time

Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s other senior manager Niklas Sandler’s share disposal.

Person subject to the notification requirement

Name: Niklas Sandler

Position: Other senior manager

Issuer: Nanoform Finland Oyj

LEI: 743700JJO2NU8LBS1592

Notification type: INITIAL NOTIFICATION

Reference number: 20620/6/6 and 20623/4/4

Transaction date: 2022-10-26

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 6990 Unit price: 2.6203 EUR

Aggregated transactions

(1): Volume: 6990 Volume weighted average price: 2.6203 EUR

Transaction date: 2022-10-27

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000330972

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 5010 Unit price: 2.599 EUR

Aggregated transactions

(1): Volume: 5010 Volume weighted average price: 2.599 EUR

For further information, please contact:

Peter Hänninen

General Counsel

peter.hanninen@nanoform.com

+358 50 353 040

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.